For the estimation of patients’ paclitaxel-metabolizing capacity, CYP2C8, CYP3A4 and CYP3A5 alleles (CYP2C8*3, CYP2C8*4, CYP3A4*1B, CYP3A4*22, CYP3A5*3) most common in Caucasian populations were identified in lung adenocarcinoma patients on paclitaxel therapy (N = 17) (Table 2). Here, CYP2C8 is linked to lung adenocarcinoma.